Aeterna Zentaris Announces Pricing of US$15.1 Million Public Offering of Common Shares and Warrants

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\nQUÉBEC CITY, Nov. 20, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced the pricing of its\n previously announced public offering of 13.1 million units (the\n \"Offering\"), with each unit consisting of one common share and one\n whole warrant to purchase one common share, at a purchase price of\n US$1.15 per unit. Each warrant will be exercisable for a period of five\n years following the issuance thereof at an exercise price of US$1.60\n per share. Net proceeds from the Offering are expected to be\n approximately US$13.7 million, after deducting underwriting commissions\n and other expenses related to the Offering.\n\n\nCanaccord Genuity Inc. is acting as the sole book-running manager for the Offering. Maxim Group LLC acted as co-manager for the Offering.\n\n\nThe Offering is expected to close on or about November 25, 2013, subject\n to customary closing conditions including, but not limited to, the\n receipt of all necessary regulatory approvals, including the approvals\n of the Toronto Stock Exchange and the NASDAQ Capital Market.\n\n\nThe Company intends to use the net proceeds from the Offering to\n continue to fund its ongoing drug development activities, primarily for\n the advancement of its zoptarelin doxorubicin (AEZS-108) program,\n secondly for its macimorelin acetate (AEZS-130) program, including the\n preparation of its commercial launch, as well as for the potential\n addition of commercialized products to the Company's pipeline, future\n negative cash flow, general corporate purposes and working capital.\n\n\nThe Offering is being conducted pursuant to the Company's effective\n shelf registration statement on Form F-10 filed with the U.S.\n Securities and Exchange Commission (the \"SEC\"), its corresponding\n Canadian base shelf prospectus and an exemption from the Autorité des marchés financiers permitting the Company to offer common shares and warrants in the\n United States. A final prospectus supplement relating to the Offering,\n along with the accompanying base shelf prospectus, will be filed with\n the SEC and with the securities regulatory authority in each of the\n provinces of Canada. Electronic copies of the preliminary and final\n prospectus supplements and the accompanying base shelf prospectus can\n be obtained on ...

More updates from Cosciens Biopharma Inc.